Semmax Financial Advisors Inc. Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Semmax Financial Advisors Inc. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 12.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,402 shares of the medical research company’s stock after purchasing an additional 1,771 shares during the quarter. Semmax Financial Advisors Inc.’s holdings in IQVIA were worth $3,468,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Marshall Wace LLP grew its holdings in shares of IQVIA by 567.0% in the second quarter. Marshall Wace LLP now owns 77,610 shares of the medical research company’s stock worth $16,410,000 after acquiring an additional 65,974 shares during the period. Providence Capital Advisors LLC increased its position in shares of IQVIA by 60.6% during the 2nd quarter. Providence Capital Advisors LLC now owns 21,767 shares of the medical research company’s stock valued at $4,602,000 after purchasing an additional 8,216 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after purchasing an additional 86,870 shares during the period. Bank of Montreal Can boosted its holdings in shares of IQVIA by 9.2% in the second quarter. Bank of Montreal Can now owns 245,711 shares of the medical research company’s stock worth $51,968,000 after buying an additional 20,799 shares during the last quarter. Finally, Lombard Odier Asset Management Europe Ltd bought a new stake in IQVIA during the second quarter valued at approximately $14,777,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several analyst reports. Royal Bank of Canada began coverage on shares of IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price target on the stock. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Robert W. Baird raised their price objective on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday. Morgan Stanley boosted their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $267.00.

IQVIA Price Performance

NYSE:IQV opened at $240.75 on Tuesday. The company has a market capitalization of $43.86 billion, a P/E ratio of 32.89, a P/E/G ratio of 2.25 and a beta of 1.49. The business’s 50-day moving average is $240.90 and its 200 day moving average is $233.81. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.